Four Helmholtz Munich scientists participate in new DFG CRC/TRR
The German Research Foundation funds a new Collaborative Research Centre (CRC)/Transregio (TRR) which aims at employing regulatory T cells to create the basis for tailor-made immunotherapies. This initiative is an alliance of the University Mainz and the Munich universities LMU and TUM together with Helmholtz Munich scientists.
Four Helmholtz Munich scientists (Prof. Daniel TDI, Dr. Serr TDI, Dr. Schubert ICB, Dr. Esser-von Bieren IAF) play a substantial role in the new TRR355 “Heterogeneity and functional specialization of regulatory T cells in different micromilieus”. This alliance of the University Mainz and the Munich universities LMU and TUM receives around 13 million euros (1.5 million euros for Helmholtz Munich) for the first four-year funding period
Co-spokesperson on behalf of LMU is Prof. Daniel, head of TDI. The scientific focus of TRR355 is on regulatory T (Treg) cells, which are key players in immune regulation and tissue function.
The goal is a deeper understanding of Treg cell heterogeneity and tissue specific function for the future development of precision immune therapies that target not only (auto)immune reactions and chronic inflammation but also organ regeneration and tissue repair.